| scholarly article | Q13442814 |
| P50 | author | Peter Laszlo Lakatos | Q42264535 |
| P2093 | author name string | Pal Miheller | |
| William Gesztes | |||
| P2860 | cites work | THE EXTRA-INTESTINAL COMPLICATIONS OF CROHNʼS DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS | Q22242792 |
| Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis | Q24241482 | ||
| Vitamin D as a therapy for colitis: a systematic review | Q26826891 | ||
| Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study | Q28204926 | ||
| Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort | Q28239892 | ||
| From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health | Q28679276 | ||
| Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease | Q31440126 | ||
| Effectiveness and safety of vitamin D in relation to bone health. | Q33310980 | ||
| Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density | Q33378962 | ||
| Reduced bone density in patients with inflammatory bowel disease | Q33617788 | ||
| Use of oral corticosteroids and risk of fractures. | Q33936232 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations | Q34152778 | ||
| AGA technical review on osteoporosis in gastrointestinal diseases. | Q34180733 | ||
| Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study | Q34268491 | ||
| 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. | Q34300668 | ||
| Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease | Q34377588 | ||
| Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older | Q34437473 | ||
| The vitamin D questions: how much do you need and how should you get it? | Q34489106 | ||
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. | Q34497449 | ||
| Diagnosis of osteoporosis and assessment of fracture risk | Q34678969 | ||
| Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology | Q35579293 | ||
| Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study | Q35598252 | ||
| Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn's disease | Q35962571 | ||
| Hormone therapy increases risk of ulcerative colitis but not Crohn's disease | Q36345322 | ||
| Dietary vitamin D intake in patients with Crohn's disease. | Q36673097 | ||
| Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial | Q37385973 | ||
| AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense | Q37393392 | ||
| Monitoring osteoporosis treatment | Q37640843 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis | Q37814539 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management | Q37814541 | ||
| Management of inflammatory bowel disease with vitamin D: beyond bone health | Q37991441 | ||
| Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement | Q38054601 | ||
| Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. | Q40176862 | ||
| A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study | Q40925443 | ||
| Noninvasive assessment of bone mineral and structure: state of the art. | Q40938448 | ||
| Evolution of osteopenia in inflammatory bowel disease | Q41650838 | ||
| The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study | Q43452900 | ||
| Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease | Q43885013 | ||
| Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study | Q43955846 | ||
| Association of dehydroepiandrosterone sulfate and testosterone deficiency with bone turnover in men with inflammatory bowel disease | Q43995994 | ||
| Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis | Q44119072 | ||
| Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease | Q44186830 | ||
| Hypomagnesaemia-induced hypocalcaemia: concentrations of parathyroid hormone, prolactin and 1,25-dihydroxyvitamin D during magnesium replenishment | Q44314277 | ||
| Longitudinal assessment of bone mineral density in children and adolescents with inflammatory bowel disease | Q44597182 | ||
| Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. | Q44660881 | ||
| Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota | Q44770708 | ||
| Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease | Q45259870 | ||
| A case-control study on risk factors of osteoporosisin patients with Crohn's disease. | Q45301218 | ||
| Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease. | Q45969720 | ||
| Determination of bone age in pediatric patients with Crohn's disease should become part of routine care | Q46665586 | ||
| A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease | Q46888780 | ||
| Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients | Q47901884 | ||
| Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis | Q49174113 | ||
| Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark | Q50571371 | ||
| Sex hormone status and bone metabolism in men with Crohn's disease. | Q50871961 | ||
| Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. | Q51020598 | ||
| Effect of Testosterone Therapy for Delayed Growth and Puberty in Boys with Inflammatory Bowel Disease | Q51903260 | ||
| Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. | Q53231896 | ||
| The effects of physical exercise on patients with Crohn's disease. | Q53555988 | ||
| Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. | Q53665843 | ||
| Vitamin D Deficiency and Insufficiency Are Common in Ulcerative Colitis Patients After Ileal Pouch–Anal Anastomosis | Q56087646 | ||
| Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial | Q57218404 | ||
| Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD cohort study | Q57711701 | ||
| Vitamin D Status and Bone Density in Recently Diagnosed Inflammatory Bowel Disease: The Manitoba IBD Cohort Study | Q57711766 | ||
| Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines1 | Q59705230 | ||
| High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease | Q61313635 | ||
| Effect of a low-impact exercise program on bone mineral density in Crohn's disease: A randomized controlled trial | Q61651201 | ||
| Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection | Q68250260 | ||
| Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) | Q69912312 | ||
| Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease | Q70917143 | ||
| Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation | Q70974043 | ||
| Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis) | Q71998928 | ||
| Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis | Q72718093 | ||
| The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study | Q73208780 | ||
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease | Q73403516 | ||
| Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors | Q74633693 | ||
| Altered bone metabolism in inflammatory bowel disease | Q74642816 | ||
| Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease | Q79792815 | ||
| Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease | Q80450044 | ||
| Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease | Q82166226 | ||
| Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease | Q83338594 | ||
| A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial | Q83567276 | ||
| Body composition and muscle strength as predictors of bone mineral density in Crohn's disease | Q83585972 | ||
| Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes | Q93627367 | ||
| P433 | issue | 4 | |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| bone disease | Q4941552 | ||
| P304 | page(s) | 296-303 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Annals of Gastroenterology | Q15758811 |
| P1476 | title | Manipulating bone disease in inflammatory bowel disease patients | |
| P478 | volume | 26 |
Search more.